Le Lézard
Classified in: Health
Subject: RCL

Bayer Inc. issues voluntary recall in Canada of specific TINACTIN® spray products due to the presence of benzene


MISSISSAUGA, ON, Oct. 1, 2021 /CNW/ - Bayer Inc. is voluntarily recalling six unexpired lots of TINACTIN® spray products in Canada with lot numbers beginning with TN to the consumer level due to the presence of benzene in some samples of the products. Benzene is not an ingredient in any of Bayer Consumer Health products. It is important to note that Bayer's decision to voluntarily recall these products is a precautionary measure and that the levels detected are not expected to cause adverse health consequences in consumers.

Risk Statement: Benzene is classified as a human carcinogen. Exposure to benzene can occur by inhalation, orally and through the skin. Depending on duration and level of exposure, it can result in cancers including leukemia and blood cancer of the bone marrow and blood disorders, which can be life-threatening. Benzene is found in the environment from natural sources and other human activity. Humans around the world are exposed to it from multiple sources and pathways, including inhalation, through the skin, and orally. To date, Bayer has no known reports of adverse events related to this recall.

The affected TINACTIN® spray products are over the counter antifungal products. The impacted products are:

Lot

Expiry

Product Name

DIN

UPC Code

TN00089

10/31/2021

Tinactin Chill Deodorant Powder Spray

DIN 02319276

056219135644

TN0053X

8/31/2022

Tinactin Chill Deodorant Powder Spray

DIN 02319276

056219135644

TN0044M

4/30/2023

Tinactin Chill Liquid Spray

DIN 02319314

056219134722

TN003J0

2/28/2022

Tinactin Aerosol Powder

DIN 00576050

068800181268

TN0057M

8/31/2022

Tinactin Aerosol Powder

DIN 00576050

068800181268

TN00798

2/28/2023

Tinactin Aerosol Powder

DIN 00576050

068800181268

There are no issues of concern with TINACTIN® cream or other Bayer products.

The recalled products are all packaged in aerosol spray cans. The products were distributed in the U.S., Puerto Rico, Canada, and Mexico through a variety of retail channels.

Bayer is notifying its distributors and retailers and is arranging for returns of all voluntarily recalled products. Consumers with affected products should dispose of them appropriately. Consumers may contact the Bayer's Recall Call Centre from 8:00 a.m. to 8:00 p.m. with questions or to request a refund by calling 1-888-473-8012 or email at [email protected].

Consumers should contact their physician or healthcare provider if they have any questions, concerns or have experienced any problems related to using these aerosol antifungal products. Adverse reactions or quality problems experienced with the use of this product may also be reported to Bayer's Recall Call Center.

This voluntary recall is being conducted with the knowledge of Health Canada.

About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4 billion euros. R&D expenses before special items amounted to 4.9 billion euros. For more information, go to www.bayer.ca.

SOURCE Bayer Inc.


These press releases may also interest you

at 06:03
The IAMStm brand, proudly part of the Mars family of brands, announced today the launch of the IAMStm Puppy Hub and Kitten Hub, two online tools featuring expert knowledge and advice for new and soon-to-be pet parents. Each Hub will bring...

at 06:00
Today, TELUS Health announced a collaboration with Nova Scotia Health (NSH) to enable residents of Nova Scotia to access their primary care information through the YourHealthNS app. This health data interoperability initiative marks the first...

at 05:30
The global Digital Healthcare Market, valued at $220.10 billion in 2024, is on a trajectory of rapid expansion, with projections indicating it will soar to $836.10 billion by 2031, growing at a compound annual growth rate (CAGR) of 21% from 2024 to...

at 05:09
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period. The...

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...



News published on and distributed by: